[1] |
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53 (3):1020-1022.
|
[2] |
Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer[J]. Eur J Cancer, 2011, 47 Suppl 3: S6-22.
|
[3] |
Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women[J]. Breast Cancer Res Treat, 2006, 97 (3): 237-244.
|
[4] |
Iwata H. Future treatment strategies for metastatic breast cancer: curable or incurable?[J]. Breast Cancer, 2012, 19 (3): 200-205.
|
[5] |
Pagani O, Senkus E, Wood W, et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?[J]. J Natl Cancer Inst, 2010, 102 (7): 456-463.
|
[6] |
Hoffmann K, Franz C, Hinz U, et al. Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors[J]. Ann Surg Oncol, 2010,17 (6):1546-1554.
|
[7] |
Dittmar Y, Altendorf-Hofmann A, Schüle S, et al. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature[J]. J Cancer Res Clin Oncol, 2013, 139 (8):1317-1325.
|
[8] |
Khanfir A, Lahiani F, Bouzguenda R, et al. Prognostic factors and survival in metastatic breast cancer: a single institution experience[J]. Rep Pract Oncol Radiother, 2013, 18 (3):127-132.
|
[9] |
Chua TC, Saxena A, Liauw W, et al. Hepatic resection for metastatic breast cancer: a systematic review[J]. Eur J Cancer, 2011, 47 (15):2282-2290.
|
[10] |
Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma[J]. Br J Surg, 2011, 98 (9):1210-1224.
|
[11] |
Ahmed M, Brace CL, Lee FT Jr, et al. Principles of and advances in percutaneous ablation[J]. Radiology, 2011, 258 (2):351-369.
|
[12] |
Vogl TJ, Farshid P, Naguib NN. Thermal ablation therapies in patients with breast cancer liver metastases: a review[J]. Eur Radiol, 2013, 23 (3): 797-804.
|
[13] |
Carrafiello G, Fontana F, Cotta E, et al. Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases[J]. Radiol Med, 2011, 116 (7):1059-1066.
|
[14] |
Livraghi T, Goldberg SN, Solbiati L, et al. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients[J]. Radiology, 2001, 220 (1): 145-149.
|
[15] |
Meloni MF, Andreano A, Laeseke PF, et al. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation: intermediate and long-term survival rates[J]. Radiology, 2009, 253 (3):861-869.
|
[16] |
Bortolotto C, Macchi S, Veronese L, et al. Radiofrequency ablation of metastatic lesions from breast cancer[J]. J Ultrasound, 2012, 15 (3):199-205.
|
[17] |
张鹏,许尔蛟,黄勇,等.射频消融联合化疗治疗乳腺癌肝转移六例疗效分析[J/CD].中华肝脏外科手术学电子杂志,2014, 3 (5):299-302.
|
[18] |
Raimondi C, Danova M, Chatzileontiadou S, et al. Role of loco-regional treatments for patients with breast cancer liver metastases[J]. Recenti Prog Med, 2009, 100 (9):424-433.
|
[19] |
Pritchard KI, Burris HA 3rd, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2[J]. Clin Breast Cancer, 2013, 13 (6):421-432.
|
[20] |
Haddley K. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer[J]. Drugs Today, 2013, 49 (11):701-715.
|